In contrast, a recent study of 572 women with early breast cancer, that had not undergone local or systemic anti-cancer treatment prior to serum collection, revealed significantly poorer outcome at a median follow-up of 5.2 years in patients with above-median M-CSF concentrations as compared to those with below-median M-CSF concentrations. Here, CSF1 is linked to breast cancer.